Publications by authors named "M Quindos-Varela"
Background: Anti-PD-1-based immunotherapy has improved outcomes in stage IIB to IV resected melanoma patients in clinical trials. However, little is known about real-world outcomes, prognostic factors and patterns of relapse.
Methods: This is a retrospective multicenter observational study including patients with resected melanoma treated with subsequent anti-PD-1-based adjuvant immunotherapy.
Article Synopsis
- Epithelial ovarian cancer (EOC) is a serious and often asymptomatic cancer, making early diagnosis challenging and leading to high mortality rates.
- Long non-coding RNAs (lncRNAs), which are long RNA molecules that do not code for proteins, are found to be deregulated in EOC and are being studied as potential biomarkers for diagnosis and prognosis.
- This research combines data from 46 studies to identify lncRNAs associated with EOC, revealing both previously known and new lncRNAs that could be significant in understanding the disease and improving clinical outcomes.
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. The current treatment for EOC involves surgical debulking of the tumors followed by a combination of chemotherapy. While most patients achieve complete remission, many EOCs will recur and develop chemo-resistance.
View Article and Find Full Text PDFIn spite of the good prognosis of patients with early-stage melanoma, there is a substantial proportion of them that develop local or distant relapses. With the introduction of targeted and immune therapies for advanced melanoma, including at the adjuvant setting, early detection of recurrent melanoma and/or second primary lesions is crucial to improve clinical outcomes. However, there is a lack of universal guidelines regarding both frequency of surveillance visits and diagnostic imaging and/or laboratory evaluations.
View Article and Find Full Text PDFHigh mobility group box B (HMGB) proteins are overexpressed in different types of cancers such as epithelial ovarian cancers (EOC). We have determined the first interactome of HMGB1 and HMGB2 in epithelial ovarian cancer (the EOC-HMGB interactome). Libraries from the SKOV-3 cell line and a primary transitional cell carcinoma (TCC) ovarian tumor were tested by the Yeast Two Hybrid (Y2H) approach.
View Article and Find Full Text PDF